We are pleased to announce that, as of May 10, 2016, the 3000th trial participant has been randomized!  We have come a long way, and we are grateful to the participants and to you for your sustained efforts and dedication to the trial. There is still much work to do but we wanted to take this opportunity to thank you and celebrate this important milestone.

What is the ISCHEMIA Study? 

  • An international comparative effectiveness study
  • The purpose of ISCHEMIA is to determine the best way to manage stable ischemic heart disease
  • Patients with moderate or severe ischemia on stress test imaging may be eligible for participation

If you are a physician and would like more information, please visit the For Physicians section. If you are a patient and would like to learn more about the ISCHEMIA study, please e-mail ischemia@nyumc.org 

Why is the ISCHEMIA Study Important?

Ischemic heart disease (IHD) is the leading cause of death and disability worldwide and affects 17,600,000 Americans, resulting in about 450,000 deaths in the United States annually. Globally, 7.2 million deaths are caused by IHD each year.

Medical therapy (medication and lifestyle changes) should always be used to treat IHD. Many doctors routinely use an invasive approach in addition to medical therapy to treat IHD; however, it is not known if this approach is better than medical therapy alone as the initial treatment of patients with stable ischemic heart disease (SIHD). ISCHEMIA is designed to find the answer. Click here to learn more about the ISCHEMIA study.

ISCHEMIA Enrollment Updates

ISCHEMIA Enrollment Updates

As of October 25th 2016, there are 3,499 participants (pts) randomized worldwide in the ISCHEMIA study. Click here to see the randomizations by country.

Congratulations To Our Top Sites!

Site name Region Study Team Rand Rate & Total Rands
Government Medical College India PI: Dr. Sajeev, Dr. Rajesh & Dr. Kumar SC: Anand, Bijith, Ravindran & Sajeev 4.0 pts/mth, 144 pts
Heart Instituto do Coracao - University of Sao Paulo Brazil PI: Dr. Hueb SC: Takiuti & Borges Miyamoto Girardi 3.5 pts/mth, 94 pts
Northwick Park Hospital-Royal Brompton Hospital UK PI: Prof. Senior SC: Kinsey, Collins, Gurunathan, Hassan, Howard, Kavalakkat & Evans 3.4 pts/mth, 147 pts
Sri Jayadeva Institute of Cardiovascular Sciences and Research India PI: Dr. Manjunath & Dr. Moorthy SC: Nataraj & Murthy 2.8 pts/mth, 94 pts
Atlanta V.A. Medical Center USA PI: Dr. Mavromatis SC: Montazeri, Lee & Patel 2.5 pts/mth, 92 pts
Coronary and Structural Heart Diseases Department, Institute of Cardiology Poland PI: Prof. Demkow SC: Chojnacka, Frelek  & Pracon 2.3 pts/mth, 102 pts
Hospital Universitario La Paz Spain PI: Dr. Lopez Sendon SC: Valbuena, Castro, La Paz Mediavilla, Valbuena & Fernandez-Figar 2.2 pts/ mth, 84 pts
Bakulev Scientific Center for Cardiovascular Surgery Russia Dr. L. Bockeria SC: O. Bockeria, & Kudzoeva 2.1 pts/mth, 79 pts
Ram Manohar Lohia Hospital India PI: Dr. Pandit SC: Bajaj, Pandit & Yadav 1.8 pts/mth, 66 pts
Montreal Heart Institute Canada PI: Gosselin SC: Vat & Proietti 1.4 pts/mth, 66 pts